Volume 88 Issue 6 | pp. 30-33
Issue Date: February 8, 2010

Antibiotics Yo-Yo

Companies score big deals but still struggle with regulatory authorities
Department: Business | Collection: Special Issue
Keywords: antibiotics, AstraZeneca, Novexel, Novartis, Pfizer, gram-negative bacteria, gram-positive bacteria, MRSA

It’s been a turbulent few years for companies developing antibiotics. Several late-stage drug candidates have suffered setbacks, and companies claim the regulatory environment has become confusing at best. But the Food & Drug Administration is beginning to offer more clarity on data it needs to approve new antibiotics. And as more development programs reach late-stage trials, biotech firms with promising drugs are finding partners ready to pay big bucks for them.

. . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society